Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today reported
financial results for its fiscal first quarter ended December 31, 2014.
Consolidated Q1 revenue of $18.4 million Non-GAAP loss from continuing operations of $0.9 million and GAAP loss from continuing operations of $3.1 million Consolidated Q1 GAAP net income of $56.1 million after taking into effect Income from discontinued operations of $59.3 million, net of tax Space Photovoltaics segment divestiture completed on December 10, 2014 Telecommunications Fiber Optics business divestiture completed on January 2, 2015 Anticipate Q2 revenue of $17 to $19 million for the remaining Broadband Fiber Optics business
ALHAMBRA, Calif., Feb.
Sonic Foundry, Inc. (NASDAQ: SOFO), the trusted leader for video
creation and management
solutions , today announced it will release results of its first
fiscal 2015 quarter Thursday, February 5 after the close of the market.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.